Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

David Goldstein

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6142-3291; OpenAlex author ID A5011795261. Sources: ClinicalTrials.gov.

Their work

Papers
72 (first author 5, last author 6)
Trials
1
Grants
0
Labs led
2
Collaborators
213
Papers, trials and grants by year

2001: 1 trial · 2002: none · 2003: none · 2004: none · 2005: none · 2006: none · 2007: none · 2008: none · 2009: none · 2010: none · 2011: none · 2012: 1 paper · 2013: 2 papers · 2014: 4 papers · 2015: 5 papers · 2016: 15 papers · 2017: 7 papers · 2018: 5 papers · 2019: 4 papers · 2020: 9 papers · 2021: 8 papers · 2022: 3 papers · 2023: 3 papers · 2024: none · 2025: 4 papers · 2026: 2 papers

Papers 50 of 72

  1. HSP47 is a potential dual cell target and prognostic factor in pancreatic cancer. Co-author DOI 10.1038/s41388-026-03865-y↗
  2. βIII-tubulin can act as a brake on extrinsic apoptosis in pancreatic cancer. Co-author DOI 10.1038/s41419-026-08657-6↗
  3. Navigating pain and appetite challenges in palliative care for pancreatic cancer: insights from a national, longitudinal consecutive cohort study. Co-author DOI 10.1007/s00520-025-09402-z↗
  4. MYH knockdown in pancreatic cancer cells creates an exploitable DNA repair vulnerability. Co-author DOI 10.1016/j.neo.2025.101138↗
  5. C-reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patients. Co-author DOI 10.1111/ajco.13993↗
  6. A phase 2, open-label, single-arm monotherapy trial of Sulfasalazine in patients with PancrEatic AdenocaRcinoma: Statistical analysis plan for the SPEAR study Last author DOI 10.64898/2025.12.04.25341652↗
  7. Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adapti… Co-author DOI 10.1016/j.eclinm.2023.101897↗
  8. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Co-author DOI 10.1200/jco.22.01134↗
  9. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of C… First author DOI 10.1200/jco.22.02770↗
  10. Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited int… Co-author DOI 10.1080/14737140.2022.2002689↗
  11. βIII-Tubulin is a Brake on Extrinsic Cell-Death in Pancreatic Cancer Co-author DOI 10.1101/2022.09.29.510034↗
  12. Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: Key role of the urokinase plasminogen activator (PLAU). Co-author DOI 10.3389/fimmu.2022.1060957↗
  13. Circulating tumour cells in pancreatic cancer: A systematic review and meta-analysis of clinicopathological implications. Co-author DOI 10.1016/j.pan.2020.11.022↗
  14. Computed Tomography Radiomics Signatures: Sensitive biomarkers for clinical decision support in pancreatic cancer- a pilot study Co-author DOI 10.1101/2021.12.03.21267217↗
  15. Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition. Co-author DOI 10.1158/0008-5472.can-20-2496↗
  16. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk an… Last author DOI 10.1186/s12885-021-08666-y↗
  17. EUS-FNA Biopsies to Guide Precision Medicine in Pancreatic Cancer: Results of a Pilot Study to Identify KRAS Wild-Type Tumours for Targeted Therapy. Co-author DOI 10.3389/fonc.2021.770022↗
  18. Does the Microenvironment Hold the Hidden Key for Functional Precision Medicine in Pancreatic Cancer? Co-author DOI 10.3390/cancers13102427↗
  19. HGF/c-Met Inhibition as Adjuvant Therapy Improves Outcomes in an Orthotopic Mouse Model of Pancreatic Cancer. Co-author DOI 10.3390/cancers13112763↗
  20. hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. Co-author DOI 10.3390/cancers13225758↗
  21. Targeting the undruggable in pancreatic cancer using nano-based gene silencing drugs. Co-author DOI 10.1016/j.biomaterials.2019.119742↗
  22. Patient-reported outcome measures (PROMs) in pancreatic cancer: a systematic review. Co-author DOI 10.1016/j.hpb.2019.09.002↗
  23. Determining the CA19-9 concentration that best predicts the presence of CT-occult unresectable features in patients with pancreatic cancer: A population-based … Co-author DOI 10.1016/j.pan.2020.07.405↗
  24. Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis. Co-author DOI 10.1038/s41416-020-0782-1↗
  25. Reply letter to comments on: Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and el… Co-author DOI 10.1038/s41416-020-1004-6↗
  26. Nomogram for Estimating Overall Survival in Patients With Metastatic Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001563↗
  27. Barriers and enablers to the implementation of protocol-based imaging in pancreatic cancer: A qualitative study using the theoretical domains framework. Co-author DOI 10.1371/journal.pone.0243312↗
  28. Targeting HGF/c-MET Axis in Pancreatic Cancer. Co-author DOI 10.3390/ijms21239170↗
  29. An Orthotopic Resectional Mouse Model of Pancreatic Cancer. Co-author DOI 10.3791/61726↗
  30. Monitoring quality of care for patients with pancreatic cancer: a modified Delphi consensus. Co-author DOI 10.1016/j.hpb.2018.08.016↗
  31. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer. Co-author DOI 10.1093/annonc/mdz200↗
  32. Evaluation of Phase II Trial Design in Advanced Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001429↗
  33. The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000002557↗
  34. Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Co-author DOI 10.1016/s1470-2045(18)30098-6↗
  35. Association between pancreatic cancer patients' perception of their care coordination and patient-reported and survival outcomes. Co-author DOI 10.1017/s1478951517000608↗
  36. Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. Co-author DOI 10.1038/s41416-018-0004-2↗
  37. Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pa… Co-author DOI 10.1038/s41416-018-0005-1↗
  38. Chemotherapy in patients with unresected pancreatic cancer in Australia: A population-based study of uptake and survival. Co-author DOI 10.1111/ajco.12862↗
  39. Rituximab to treat gemcitabine-induced hemolytic-uremic syndrome (HUS) in pancreatic adenocarcinoma: a case series and literature review. Last author DOI 10.1007/s00280-016-3123-6↗
  40. Anxiety, depression and quality of life in people with pancreatic cancer and their carers. Co-author DOI 10.1016/j.pan.2017.01.008↗
  41. Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group … Co-author DOI 10.1080/14737140.2017.1369882↗
  42. Circulating pancreatic stellate (stromal) cells in pancreatic cancer-a fertile area for novel research. Co-author DOI 10.1093/carcin/bgx030↗
  43. Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine: An Exploratory Analysis From a Phase 3 Study. Co-author DOI 10.1097/mpa.0000000000000742↗
  44. MutY-Homolog (MYH) inhibition reduces pancreatic cancer cell growth and increases chemosensitivity. Co-author DOI 10.18632/oncotarget.13985↗
  45. Targeting the HGF/c-MET pathway: stromal remodelling in pancreatic cancer. Co-author DOI 10.18632/oncotarget.20822↗
  46. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Wi… Co-author DOI 10.1001/jama.2016.4324↗
  47. Risk factors for current and future unmet supportive care needs of people with pancreatic cancer. A longitudinal study. Co-author DOI 10.1007/s00520-016-3212-4↗
  48. Determinants of Outcomes Following Resection for Pancreatic Cancer-a Population-Based Study. Co-author DOI 10.1007/s11605-016-3157-4↗
  49. Key role of pancreatic stellate cells in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2015.10.035↗
  50. Delineating the Role of βIV-Tubulins in Pancreatic Cancer: βIVb-Tubulin Inhibition Sensitizes Pancreatic Cancer Cells to Vinca Alkaloids. Co-author DOI 10.1016/j.neo.2016.10.011↗

Trials 1

  1. Two Chemotherapy Regimens Compared With Observation in Treating Patients With Completely Resected Pancreatic Cancer NCT00058201↗

Closest collaborators

The 25 strongest of 213 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Minoti Vivek Apte · 15 shared papers, 2014–2026 · strength 1.57
  2. Joshua A. McCarroll · 12 shared papers, 2014–2026 · strength 1.31
  3. Phoebe A. Phillips · 12 shared papers, 2014–2026 · strength 1.31
  4. Jeremy S. Wilson · 13 shared papers, 2014–2022 · strength 1.28
  5. George Sharbeen · 11 shared papers, 2014–2026 · strength 1.26
  6. Val Gebski · 10 shared papers, 2012–2026 · strength 1.23
  7. Koroush Shahsavar Haghighi · 9 shared papers, 2016–2026 · strength 1.19
  8. Zhihong Xu · 12 shared papers, 2014–2022 · strength 1.13
  9. John Kokkinos · 7 shared papers, 2020–2026 · strength 1.05
  10. Srinivasa P. Pothula · 11 shared papers, 2014–2021 · strength 1.00
  11. Neil Donald Merrett · 14 shared papers, 2015–2020 · strength 0.98
  12. Amber L. Johns · 9 shared papers, 2013–2026 · strength 0.98
  13. Anthony James Gill · 7 shared papers, 2013–2026 · strength 0.86
  14. Rachel Ε. Neale · 12 shared papers, 2016–2020 · strength 0.86
  15. Mert Erkan · 6 shared papers, 2015–2026 · strength 0.83
  16. Tony Pang · 6 shared papers, 2017–2022 · strength 0.69
  17. Marina Pajic · 5 shared papers, 2013–2026 · strength 0.60
  18. Jennifer P. Morton · 4 shared papers, 2021–2026 · strength 0.59
  19. Andrew P. Barbour · 5 shared papers, 2015–2025 · strength 0.56
  20. Australian Pancreatic Cancer Genome Initiative · 3 shared papers, 2020–2026 · strength 0.50
  21. Helen M. Gooden · 8 shared papers, 2016–2018 · strength 0.49
  22. Monika Janda · 8 shared papers, 2016–2018 · strength 0.49
  23. Vanessa L. Beesley · 8 shared papers, 2016–2018 · strength 0.49
  24. James G. Kench · 5 shared papers, 2015–2025 · strength 0.48
  25. Elizabeth A. Burmeister · 7 shared papers, 2016–2020 · strength 0.48

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.